Courtagen Life Sciences Collaborates with Astellas Pharma for Mitochondrial Disorder Drug Development

Courtagen enters data partnership with Astellas for early stage therapeutic development program to address mitochondrial disease.

WOBURN, Mass.--()--Courtagen Life Sciences, Inc., a molecular information company that brings comprehensive neurological genome analysis to routine clinical care, announced a collaboration with Astellas Pharma Inc. Courtagen will utilize its molecular information platform to aid in the development of a predictive model to support early stage therapeutic development for mitochondrial disease.

“Astellas and Courtagen share a commitment to innovative clinical solutions that address the needs of patients suffering from mitochondrial based disorders,” states Brian McKernan, Chief Executive Officer of Courtagen. “Courtagen was founded on the idea of helping patients suffering from mitochondrial disorders, and now we are able to utilize our unique capability to correlate clinical data with specific genomic alterations and aid in the development of targeted therapeutics.”

To learn more, follow Courtagen on social media with Facebook, Twitter, and Instagram.

About Astellas
Astellas Pharma Inc., based in Tokyo, Japan, is a company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceutical products. We focus on Urology, Oncology, Immunology, Nephrology and Neuroscience as prioritized therapeutic areas while advancing new therapeutic areas and discovery research leveraging new technologies/modalities. We are also creating new value by combining internal capabilities and external expertise in the medical/healthcare business. Astellas is on the forefront of healthcare change to turn innovative science into value for patients. For more information, please visit our website at http://www.astellas.com/en.

About Courtagen Life Sciences, Inc.
Courtagen Life Sciences, Inc., located in Woburn, MA, is a CLIA/CAP certified molecular information company focused on the diagnosis of a range of neurological disorders. Courtagen operates a highly sophisticated Next Generation DNA Sequencing, bioinformatics, and clinical interpretation business. Courtagen’s work helps physicians elucidate the linkages between the genotypes and phenotypes of various neurological diseases. For more information, please visit http://www.courtagen.com/.

Contacts

Courtagen Life Sciences
Mike Catalano, 877-395-7608
press@courtagen.com

Contacts

Courtagen Life Sciences
Mike Catalano, 877-395-7608
press@courtagen.com